DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection in Pregnant Women

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

August 31, 2023

Study Completion Date

September 10, 2023

Conditions

HIV InfectionsPregnancy RelatedMother to Child Transmission

Interventions

DRUG

Dolutegravir plus lamivudine in a FDC

All participants will receive an ART regimen composed by Lamivudine plus Dolutegravir in a single pill (FDC)

Trial Locations (1)

Fundação Bahiana de Infectologia, Salvador